http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180061318-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a695659dff59e19b48ff41f2a54442dc |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C201-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a03faa9af9ecf41d17cb9173ad7d740 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21ce0a502bda3c402cba257180992b48 |
publicationDate | 2018-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-20180061318-A |
titleOfInvention | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors |
abstract | The present invention provides a compound that inhibits or modulates the activity of p70S6 kinase, wherein the compound is a compound of formula (1) or a salt, tautomer or N-oxide thereof. here, One of Y and Z is R < 3 > and the other is Ar < 2 >; Q 1 is an optionally substituted C 1-8 alkylene group; Wherein the carbon atom of the C 1-8 alkylene group may optionally be replaced by a cyclopropane-1,1-diyl or cyclobutane-1,1-diyl group, provided that the total number of carbon atoms in the alkylene group The number does not exceed eight; Q 2 is a bond or an optionally substituted C 1-8 alkylene group R 1 is selected from hydrogen, NR x R y and the group Cy 1 ; R x and R y are each selected from hydrogen, C 1-4 hydrocarbyl or hydroxy-C 1-4 hydrocarbyl; Or NR x R y form an optionally substituted 4 to 7 membered heterocyclic ring; Cy 1 is an optionally substituted C-linked 3 to 7 membered monocyclic non-aromatic carbocyclic or heterocyclic; R 2 and R 4 are each selected from hydrogen, fluorine, chlorine, optionally substituted C 1-2 alkyl and optionally substituted C 1-2 alkoxy; R 3 is selected from hydrogen, fluorine, chlorine, optionally substituted C 1-2 alkyl and optionally substituted C 1-2 alkoxy; Ar 1 is an optionally substituted monocyclic 5 or 6 membered aryl or heteroaryl ring; Ar 2 is an optionally substituted bicyclic 8 to 11-membered heteroaryl group. The compounds are useful in the treatment of diseases or conditions selected from medicaments, for example, cancer, neurodevelopmental disorders and neurodegenerative diseases. |
priorityDate | 2015-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 728.